Matulane

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Matulane
Generic name
PROCARBAZINE HYDROCHLORIDE
Manufacturer
Leadiant Biosciences, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
1aa75a3a-18c9-49e1-91a6-293d0b7da756
SPL ID
63cfdccc-7bfd-44a1-894e-236292c7ea47
Version
12
Effective date
2026-10-09
Source export date
2026-11-13
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:32:24
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Myelosuppression: Severe neutropenia, anemia, and thrombocytopenia can occur. Obtain complete blood counts prior to initiation of MATULANE ( 5.1 ) Secondary Malignancies: Lung cancer, myelodysplastic syndrome, acute myeloid leukemia, and non-Hodgkin lymphoma have been reported. Monitor patients for the development of secondary malignancies during and after treatment with MATULANE. ( 5.2 ) Use in Patients with Renal or Hepatic Impairment: Evaluate renal and hepatic function. Closely monitor for adverse reactions. ( 5.3 ) Risk of Disulfiram-like Reaction Due to Concomitant Use with Alcohol : Advise patients to avoid consumption of alcohol products containing propylene glycol before, after, and during treatment with MATULANE. ( 5.4 ) Infertility : Male and female reproductive function and fertility may be impaired in patients treated with MATULANE. Advise patients on the potential risks for infertility. ( 5.5 , 8.3 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.6 , 8.1 , 8.3 ) 5.1 Myelosuppression Matulane can cause myelosuppression, including severe neutropenia, anemia, and thrombocytopenia. Obtain complete blood counts prior to initiation of MATULANE and monitor patients during treatment for clinical complications due to myelosuppression. During treatment with MATULANE, monitor hemoglobin, hematocrit, white blood count (WBC) including differential, reticulocytes, and platelets weekly or as clinically necessary. Myelosuppression often occurs 2 to 8 weeks after the start of MATULANE treatment. If severe myelosuppression occurs, withhold MATULANE until clinically stable, or permanently discontinue depending on severity [see Dosage and Administration (2.2) ] . If radiation or a chemotherapeutic agent known to have myelosuppressive activity has been used, an interval of one month or longer without such therapy is recommended before starting treatment with MATULANE. The length of this interval may also be determined by evidence of bone marrow recovery based on successive bone marrow studies. 5.2 Secondary Malignancies Secondary malignancies have been reported in patients treated with MATULANE when used in combination with other chemotherapy, including lung cancer, myelodysplastic syndrome, acute myeloid leukemia, and non-Hodgkin Lymphoma. The risks of secondary lung cancer from treatment appear to be increased by tobacco use. Monitor patients for the development of secondary malignancies during and after treatment with MATULANE. 5.3 Use in Patients with Renal or Hepatic Impairment Increased adverse reactions may occur if Matulane is used in patients with renal or hepatic impairment. Evaluate renal and hepatic function prior to beginning therapy. Repeat urinalysis, transaminase, alkaline phosphatase and blood urea nitrogen tests at least weekly and as clinically indicated. When appropriate, consider hospitalization for the initial course of treatment. 5.4 Risk of Disulfiram-like Reaction Due to Concomitant Use with Alcohol MATULANE can cause a disulfiram-like reaction in patients who consume alcohol during treatment with MATULANE. Advise patients to avoid consumption of alcohol or products containing propylene glycol before, after, and during treatment with MATULANE. 5.5 Infertility Male and female reproductive function and fertility may be impaired in patients treated with MATULANE. Patients treated with MATULANE when used in combination with other chemotherapy have reported azoospermia and premature ovarian failure. Advise patients on the potential risks for infertility [see Use in Specific Populations (8.3) ] . 5.6 Embryo-Fetal Toxicity Based on findings from human case reports and animal studies, MATULANE can cause fetal harm when administered to a pregnant woman. There are case reports of malformations in the offspring of women who were exposed to procarbazine hydrochloride in combination with other antineoplastic agents during pregnancy. In reproductive studies in rats, procarbazine hydrochloride caused adverse developmental outcomes including embryo-fetal mortality, structural abnormalities, and neurogenic tumors. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with MATULANE. Advise males with female partners of reproductive potential to use effective contraception during treatment with MATULANE [see Use in Specific Populations (8.1 , 8.3) ].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail elsewhere in the labeling. Myelosuppression [see Warnings and Precautions (5.1) ]. Secondary Malignancies [see Warnings and Precautions (5.2) ] . Risk of Disulfiram-like Reaction Due to Concomitant Use with Alcohol [see Warnings and Precautions (5.3) ] . Infertility [see Warnings and Precautions (5.4) ]. The following adverse reactions associated with the use of MATULANE were identified in clinical studies or post-marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions for MATULANE are neutropenia, anemia, thrombocytopenia, nausea, and vomiting. Other adverse reactions are: Hematologic: Pancytopenia, eosinophilia, hemolytic anemia Vascular: Petechiae, purpura, epistaxis, hemoptysis Hepatobiliary: Hepatic dysfunction, jaundice Gastrointestinal: Stomatitis, hematemesis, melena, diarrhea, dysphagia, anorexia, abdominal pain, constipation, dry mouth Neurologic: Coma, convulsions, neuropathy, ataxia, paresthesia, nystagmus, diminished reflexes, falling, foot drop, headache, dizziness, unsteadiness, slurred speech Cardiovascular: Hypotension, tachycardia, syncope Ophthalmic: Retinal hemorrhage, papilledema, photophobia, diplopia, inability to focus Respiratory: Pneumonitis, pleural effusion, cough, hoarseness Dermatologic: Herpes, dermatitis, pruritus, alopecia, hyperpigmentation, rash, urticaria, flushing Allergic: Generalized allergic reactions Genitourinary: Hematuria, urinary frequency, nocturia Musculoskeletal: Pain including myalgia and arthralgia, tremors Psychiatric: Hallucinations, depression, apprehension, nervousness, confusion, nightmares, insomnia Endocrine: Gynecomastia in prepubertal and early pubertal boys Miscellaneous: Intercurrent infections, hearing loss General: Pyrexia, diaphoresis, lethargy, weakness, fatigue, edema, chills, drowsiness Neoplasms: Secondary lung cancer, acute myelocytic leukemia, myelodysplastic syndrome, malignant myelosclerosis The most common adverse reactions are neutropenia, anemia, thrombocytopenia, nausea, and vomiting ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Leadiant Biosciences, Inc. at 1-888-393-4584 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.